Neuphoria Therapeutics Inc. (NEUP)

NASDAQ: NEUP · Real-Time Price · USD
5.07
-0.10 (-1.93%)
Apr 30, 2025, 4:00 PM EDT - Market closed
Market Cap 8.91M
Revenue (ttm) 662,715
Net Income (ttm) -8.21M
Shares Out 1.76M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,823
Open 5.06
Previous Close 5.17
Day's Range 5.04 - 5.20
52-Week Range 2.12 - 15.24
Beta n/a
Analysts Strong Buy
Price Target 21.00 (+314.2%)
Earnings Date May 15, 2025

About NEUP

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 24
Stock Exchange NASDAQ
Ticker Symbol NEUP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for NEUP stock is "Strong Buy" and the 12-month stock price forecast is $21.0.

Price Target
$21.0
(314.20% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Initiation by Merck of a Phase 2 trial in Alzheimer's disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company's pipeline diversification beyond BNC210 US $15M milesto...

15 days ago - GlobeNewsWire

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology developing impactful treatments for neuropsy...

2 months ago - GlobeNewsWire

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator Milestone payment tr...

2 months ago - GlobeNewsWire

Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq

BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangemen...

4 months ago - GlobeNewsWire